Ruxolitinib (Opzelura)

What is ruxolitinib?

Ruxolitinib is a topical JAK inhibitor designed to modulate the immune system and reduce skin inflammation. While it is FDA-approved for treating atopic dermatitis, it also has potential off-label applications for conditions like alopecia areata and vitiligo.

What are possible side effects of ruxolitinib?

Unlike steroids, ruxolitinib is considered safer for application on sensitive body areas, such as the face and genital regions. The medication carries a label warning for risks similar to those associated with oral JAK inhibitors, including blood clots, serious infections, and cardiovascular events. However, it remains uncertain whether topical application on a limited body surface area carries the same level of risk as its oral counterparts.

How is ruxolitinib used?

Ruxolitinib is formulated as a cream and should be applied twice daily. A thin layer of the cream should be spread over the affected skin areas.